Marien-Hospital Wesel, Research Institute, Department of Pediatrics, Wesel, Germany.
J Allergy Clin Immunol. 2013 Jun;131(6):1565-73. doi: 10.1016/j.jaci.2013.01.006. Epub 2013 Mar 16.
The long-term effect of nutritional intervention with hydrolysate infant formulas on allergic manifestations in high-risk children is uncertain.
We sought to investigate the effect of hydrolysate infant formulas on allergic phenotypes in children with family history of allergies at school age.
We analyzed data from participants of the prospective German Infant Nutritional Intervention study after 10 years of follow-up. At birth, children were randomly assigned to receive, for the first 4 months, one of 4 blinded formulas as breast milk substitute, if necessary: partially hydrolyzed whey formula (pHF-W), extensively hydrolyzed whey formula (eHF-W), extensively hydrolyzed casein formula (eHF-C), or standard cow's milk formula. Outcomes were parent-reported, physician-diagnosed allergic diseases. Log-binomial regression models were used for statistical analysis.
The relative risk for the cumulative incidence of any allergic disease in the intention-to-treat analysis (n = 2252) was 0.87 (95% CI, 0.77-0.99) for pHF-W, 0.94 (95% CI, 0.83-1.07) for eHF-W, and 0.83 (95% CI, 0.72-0.95) for eHF-C compared with standard cow's milk formula. The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.00), 0.91 (95% CI, 0.76-1.10), and 0.72 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis (n = 988) effects were stronger. The period prevalence of AD at 7 to 10 years was significantly reduced with eHF-C in this analysis, but there was no preventive effect on asthma or allergic rhinitis.
The significant preventive effect on the cumulative incidence of allergic diseases, particularly AD, with pHF-W and eHF-C persisted until 10 years without rebound, whereas eHF-W showed no significant risk reduction. There is insufficient evidence of ongoing preventive activity at 7 to 10 years of age.
水解配方奶粉对高过敏风险儿童的长期营养干预效果尚不确定。
本研究旨在探讨水解配方奶粉对有过敏家族史的儿童在学龄期的过敏表型的影响。
我们对前瞻性德国婴儿营养干预研究的参与者进行了 10 年的随访后分析。出生时,如果需要,儿童被随机分配接受 4 个月的 4 种配方奶中的 1 种作为母乳替代物:部分水解乳清配方(pHF-W)、深度水解乳清配方(eHF-W)、深度水解酪蛋白配方(eHF-C)或标准牛奶配方。结局为父母报告、医生诊断的过敏疾病。采用对数二项式回归模型进行统计分析。
意向治疗分析(n=2252)中,任何过敏疾病的累积发病率的相对风险分别为 pHF-W 组为 0.87(95%CI,0.77-0.99),eHF-W 组为 0.94(95%CI,0.83-1.07),eHF-C 组为 0.83(95%CI,0.72-0.95),与标准牛奶配方相比。特应性皮炎(AD)的相应数字分别为 0.82(95%CI,0.68-1.00)、0.91(95%CI,0.76-1.10)和 0.72(95%CI,0.58-0.88)。在方案分析(n=988)中,效果更强。在这项分析中,eHF-C 显著降低了 7 至 10 岁时 AD 的期患病率,但对哮喘或过敏性鼻炎没有预防作用。
pHF-W 和 eHF-C 对过敏性疾病,特别是 AD 的累积发病率有显著的预防作用,且持续至 10 年,无反弹现象,而 eHF-W 则无显著的风险降低。7 至 10 岁时持续预防作用的证据不足。